Kinetic and thermodynamic studies of ligand-receptor interactions are essential for increasing the understanding of receptor activation mechanisms and drug behavior. The characterization of molecular interactions on living cells in real-time goes beyond most current binding assays, and provides valuable information about the dynamics and underlying mechanism of the molecules in a living system. The effect of temperature on interactions in cell-based assays is, however, rarely discussed. In the present study, the effect of temperature on binding of monoclonal antibodies, cetuximab and pertuzumab to specific receptors on living cancer cells was evaluated, and the affinity and kinetics of the interactions were estimated at selected key temperatures. Changes in the behavior of the interactions, particularly in the on- and off-rates were observed, leading to greatly extended time to reach the equilibrium at 21°C compared with at 37°C. However, the observed changes in kinetic characteristics were less than a factor of 10. It was concluded that it is possible to conduct real-time measurements with living cells at different temperatures, and demonstrated that influences of the ambient temperature on the interaction behavior are likely to be less than one order of magnitude.

Department of Biophysics and Physical Chemistry Faculty of Pharmacy Charles University 500 05 Hradec Králové Czech Republic

Department of Engineering and Chemical Sciences Karlstad University 651 88 Karlstad Sweden

Department of Immunology Genetics and Pathology Uppsala University 75185 Uppsala Sweden

Ridgeview Instruments AB Vänge 74020 Uppsala Sweden

See more in PubMed

Liu JKH. The history of monoclonal antibody development-Progress, remaining challenges and future innovations. Ann Med Surg (Lond) 2014;3:113–116. doi: 10.1016/j.amsu.2014.09.001. PubMed DOI PMC

Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009;158:1–9. doi: 10.1111/j.1365-2249.2009.03992.x. PubMed DOI PMC

Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371. doi: 10.1038/nrm1911. PubMed DOI

Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11:1000–1017. doi: 10.2174/138945010791591395. PubMed DOI PMC

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al. ML18147 Study investigators: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14:29–37. doi: 10.1016/S1470-2045(12)70477-1. PubMed DOI

Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–311. doi: 10.1016/j.ccr.2005.03.003. PubMed DOI

van Dongen GA, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379–1389. doi: 10.1634/theoncologist.12-12-1379. PubMed DOI

Arruebo M, Valladares M, González-Fernández Á. Antibody-conjugated nanoparticles for biomedical applications. J Nanomater. 2009;2009 doi: 10.1155/2009/439389. DOI

Andersson K. Bringing time into molecular and cellular biology. J Anal Oncol. 2013;2:65–68.

Kastritis PL, Bonvin AMJJ. On the binding affinity of macromolecular interactions: Daring to ask why proteins interact. J R Soc Interface. 2013;10:20120835. doi: 10.1098/rsif.2012.0835. PubMed DOI PMC

Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H. Biophysics in drug discovery: Impact, challenges and opportunities. Nat Rev Drug Discov. 2016;15:679–698. doi: 10.1038/nrd.2016.123. PubMed DOI

Björke H, Andersson K. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl Radiat Isot. 2006;64:32–37. doi: 10.1016/j.apradiso.2005.06.007. PubMed DOI

Stenberg J, Spiegelberg D, Karlsson H, Nestor M. Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6. Nucl Med Biol. 2014;41:140–147. doi: 10.1016/j.nucmedbio.2013.10.010. PubMed DOI

Spiegelberg D, Stenberg J, Haylock AK, Nestor M. A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties. Nucl Med Biol. 2016;43:12–18. doi: 10.1016/j.nucmedbio.2015.09.004. PubMed DOI

Nath N, Godat B, Zimprich C, Dwight SJ, Corona C, McDougall M, Urh M. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods. 2016;431:11–21. doi: 10.1016/j.jim.2016.02.001. PubMed DOI

Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old LJ, Toomre DK, Scott AM. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: A novel anti-epidermal growth factor receptor antibody. Neoplasia. 2007;9:1099–1110. doi: 10.1593/neo.07721. PubMed DOI PMC

Winquist J, Geschwindner S, Xue Y, Gustavsson L, Musil D, Deinum J, Danielson UH. Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors. Biochemistry. 2013;52:613–626. doi: 10.1021/bi301333z. PubMed DOI

Shuman CF, Hämäläinen MD, Danielson UH. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit. 2004;17:106–119. doi: 10.1002/jmr.655. PubMed DOI

Geitmann M, Danielson UH. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorg Med Chem. 2007;15:7344–7354. doi: 10.1016/j.bmc.2007.08.018. PubMed DOI

Reverberi R, Reverberi L. Factors affecting the antigen-antibody reaction. Blood Transfus. 2007;5:227–240. PubMed PMC

Björkelund H, Gedda L, Andersson K. Comparing the epidermal growth factor interaction with four different cell lines: Intriguing effects imply strong dependency of cellular context. PLoS One. 2011;6:e16536. doi: 10.1371/journal.pone.0016536. PubMed DOI PMC

Bondza S, Stenberg J, Nestor M, Andersson K, Björkelund H. Conjugation effects on antibody-drug conjugates: Evaluation of interaction kinetics in real time on living cells. Mol Pharm. 2014;11:4154–4163. doi: 10.1021/mp500379d. PubMed DOI

Gedda L, Björkelund H, Andersson K. Real-time immunohistochemistry analysis of embedded tissue. Appl Radiat Isot. 2010;68:2372–2376. doi: 10.1016/j.apradiso.2010.06.003. PubMed DOI

Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem. 2012;23:1802–1811. doi: 10.1021/bc3000645. PubMed DOI

Pa̧zik R, Andersson R, Kȩpiński L, Nedelec J-M, Kessler VG, Seisenbaeva GA. Surface functionalization of the metal oxide nanoparticles with biologically active molecules containing phosphonate moieties. Case study of BaTiO 3. J Phys Chem C. 2011;115:9850–9860. doi: 10.1021/jp2000656. DOI

Barta P, Malmberg J, Melicharova L, Strandgård J, Orlova A, Tolmachev V, Laznicek M, Andersson K. Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. Int J Oncol. 2012;40:1677–1682. PubMed

Fornstedt T. Characterization of adsorption processes in analytical liquid-solid chromatography. J Chromatogr A. 2010;1217:792–812. doi: 10.1016/j.chroma.2009.12.044. PubMed DOI

Ståhlberg J, Henriksson H, Divne C, Isaksson R, Pettersson G, Johansson G, Jones TA. Structural basis for enantiomer binding and separation of a common β-blocker: Crystal structure of cellobiohydrolase Cel7A with bound (S)-propranolol at 1.9 A resolution. J Mol Biol. 2001;305:79–93. doi: 10.1006/jmbi.2000.4237. PubMed DOI

Fornstedt T, Guiochon G. Nonlinear effects in LC and Chiral LC. Anal Chem. 2001;73:608A–617A. doi: 10.1021/ac012533b. PubMed DOI